Literature DB >> 18370923

Anti-inflammatory actions of intravenous immunoglobulin.

Falk Nimmerjahn1, Jeffrey V Ravetch.   

Abstract

The remarkable success story of the therapeutic application of pooled immunoglobulin G (IgG) preparations from thousands of donors, the so-called intravenous IgG (IVIG) therapy, to patients with a variety of hematological and immunological disorders began more than half a century ago. Since then, the use of this primary blood product has increased constantly, resulting in the serious danger of shortages in supply. Despite its widespread use and therapeutic success, the mechanisms of action, especially of the anti-inflammatory activity, are only beginning to be understood. In this review, we summarize the clinical use of IVIG for different diseases and discuss recent data on the molecular mechanisms that might explain how this potent drug mediates its activity in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18370923     DOI: 10.1146/annurev.immunol.26.021607.090232

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  193 in total

1.  Predicting the clinical efficacy and potential adverse effects of a humanized anticocaine monoclonal antibody.

Authors:  Andrew B Norman; William J Ball
Journal:  Immunotherapy       Date:  2012-03       Impact factor: 4.196

Review 2.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

Review 3.  The role of sialic acid as a modulator of the anti-inflammatory activity of IgG.

Authors:  Sybille Böhm; Inessa Schwab; Anja Lux; Falk Nimmerjahn
Journal:  Semin Immunopathol       Date:  2012-03-22       Impact factor: 9.623

Review 4.  The role of IgA and IgA Fc receptors as anti-inflammatory agents.

Authors:  Renato C Monteiro
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

Review 5.  Immunomodulation by intravenous immunoglobulin: role of regulatory T cells.

Authors:  Mohan S Maddur; Shivashankar Othy; Pushpa Hegde; Janakiraman Vani; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

Review 6.  A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs.

Authors:  Robert M Anthony; Jeffrey V Ravetch
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

Review 7.  Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute.

Authors:  Miglena G Prabagar; Hyeong-jwa Choi; Jin-Yeon Park; Sohee Loh; Young-Sun Kang
Journal:  Clin Exp Med       Date:  2013-09-01       Impact factor: 3.984

Review 8.  Chemical and chemoenzymatic synthesis of glycoproteins for deciphering functions.

Authors:  Lai-Xi Wang; Mohammed N Amin
Journal:  Chem Biol       Date:  2014-01-16

Review 9.  The challenge and promise of glycomics.

Authors:  Richard D Cummings; J Michael Pierce
Journal:  Chem Biol       Date:  2014-01-16

Review 10.  Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives.

Authors:  Bernhard Maisch; Sabine Pankuweit
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.